Summary This randomised phase II study was performed in order to evaluate the effectiveness of a weekly chemotherapy regimen in advanced prostatic carcinoma patients (stage D2) refractory to hormonal therapy. Seventy-two cases were studied: they were randomised in a 2:1 ratio to receive either epirubicin (30 mgm 2 weekly) or doxorubicin (25 mg m weekly); 48 patients received epirubicin and 24 received doxorubicin.
Prostatic cancer is a common neoplasm in which the results of treatment remain somewhat controversial. Both surgery and radiation therapy have potentially curative roles, provided the tumour is confined to the prostate itself. However, once lymphnodes are involved, the possibility of dissemination is high. The usual sites of distant metastases include the skeleton, liver and lungs.
Hormonal therapy remains a standard and effective systemic approach to disseminated disease (Klein, 1979; Fossa et al., 1990; Sharifi et al., 1990) .
Patients who fail to respond to hormonal treatment, or relapse after an initial response should be considered for chemotherapy. Among antineoplastic agents, doxorubicin appears to be one of the best single agents for prostatic cancer, but its cardiotoxicity limits its use especially in this aged patient group and consequently, alternatives are desirable (Dewys et al., 1977; Von-Hoff et al., 1982) .
In the past decade, Torti et al. (1983) reported that a weekly regimen with low doses of doxorubicin, instead of the conventional one on a 3-week basis, is able to strongly reduce side effects, particularly cardiotoxicity. Subsequently, preliminary studies with epirubicin (the 4'-epimer of doxorubicin) have suggested that this new anthracycline derivative is less cardiotoxic than doxorubicin while achieving similar antitumor effects (Torti et al., 1986; Francini et al., 1989) . It is therefore reasonable to assume that a weekly schedule with epirubicin could further decrease anthracycline-induced side effects and the risk of cardiotoxicity. The aim of the study was to test this hypothesis in prostatic cancer relapsed after hormonal therapy.
Skeletal metastases in prostatic cancer are usually osteoblastic, and make the assessment of response to treatment particularly difficult. This is one of the major problems in monitoring advanced prostatic cancer; very often different methods and criteria of response evaluation have produced conflicting results. Currently, the most widely used response criteria are those of National Prostatic Cancer Project (NPCP) (Slack & Murphy, 1984) , but these criteria are insufficient for monitoring the turnover of osteoblastic bone metastases. In fact, radiographic resolution of osteoblastic lesions is rare, while the detection of scintigraphic changes requires careful attention to technical details of scanning (Levenson et al., 1983 Patients were considered evaluable for response and toxicity only after they had undergone at least six courses of chemotherapy.
Blood and urine parameters It is well-known that the early effects of treatment on the morphologic evaluation of bone metastases cannot be detected by bone scans or X-ray; for early detection, one must rely on the measurement of biochemical indices both of tumour cell proliferation and of bone turnover (Ahmann et al., 1987; Francini et al., 1988; Coleman, 1991; Francini et al., 1992) .
Thus, the following parameters were evaluated in all subjects, before the start of chemotherapy, after three, six, nine, and 12 courses, and then every 2 months. -Serum acid phosphatase (Acid Ph.), a significant marker in prostatic cancer (Reif et al., 1973) Caniggia & Vattimo (1980)-n.v.: 33.3 ± 7.4 (%). -Serum bone Gla-protein (BGP), which reflects osteoblastic activity (Price et al., 1981) The following parameters were measured at weekly intervals: complete blood cell count, pain intensity and perfor- Response assessment The most widely used response criteria are those of NPCP (Table II ). An overall evaluation of the responses was made according to modified NPCP group criteria; the modifications added by us are shown in Table III .
Only the patients who achieved a partial remission were considered 'responders'.
Histological
Histological analysis of bone metastases was performed using transiliac bone biopsy specimens in patients with extensive lesions of the basin: (i) 20 patients before starting epirubicin and then in 12 responders after 12 courses; (ii) ten patients before starting doxorubicin and in five responders after 12 courses (Faugere & Malluche, 1983) . The results, before and after chemotherapy, in terms of neoplastic invasion and of new bone formation, were compared by the methods of Weibel (1979) and Frost (1969) .
Toxicity and quality of life Toxicity was evaluated according to World Health Organization (WHO) criteria (1979) .
The systolic indices of cardiac performance were measured by the use of pre-ejection period/left ventricular ejection time (PEP/LVET), according to Hassan & Turner (1983) (PEP/ LVET ratio in a normal adult (0.35 in our laboratory).
Treatment was delayed if the leukocytes were <2,500 mm 3, platelets <50,000, bilirubin >3 mg dl-' and if the PEP/LVET ratio increased to > 10% of normal values. During the first 12 courses of chemotherapy, a maximum delay of 1 week was allowed; thereafter, a maximum delay of 3 weeks was allowed. In case of lower values of leukocyte and platelet count and in case of congestive heart failure, treatment was discontinued. No dose reductions were made.
To assess quality of life, patients completed a questionnaire regarding physical symptoms, functional activity, family and emotional well-being, treatment satisfaction and occupational functioning on a weekly basis.
Statistics
Statistical analyses of biochemical measurements were performed using the Student's t test for paired samples, comparing pretreatment vs post-treatment values in both responding and non-responding patients.
Response rates were compared by Fisher's exact test; a P value of 0.05 was assumed to indicate statistical significance. Survival curves were determined by the Kaplan & Meier method (1958) and further comparisons based on the logrank statistics (Peto et al., 1977) . Data were collected and analysed with the aid of statistical analysis software (Release 1.1 Level 2 for Digital VAX/UMS, December 23, 1986, SPSS Inc. 444, North Michigan Avenue, Chicago, IL 60611, USA).
Results
All of the 72 eligible patients were evaluated for survival and, of these, 66 were evaluable for response and toxicity: 45 receiving epirubicin and 21 receiving doxorubicin. The median number of administered courses was 16 for the epirubicin arm (range 4-38) and nine for the doxorubicin arm (range 3-25).
The response rate in epirubicin-treated patients (17/45: 37.7%) (95% confidence limit; 23% to 50%) was similar to the doxorubicin group (7/21: 33.3%) (94% confidence limit; 13% to 53%) (P = 0.51) (Table IV) .
Performance status showed a rapid improvement in all responding patients and in the majority of those who achieved stable disease. These patients had a notable improvement in physical symptoms, such as bone pain, weakness and anorexia, in functional conditions, such as capacity to work and to enjoy one's free time, and in emotional well being. Most of the patients showed treatment satisfaction.
The bone markers (WBR%, BGP, Alk Ph, UHOP/Cr) and the prostatic tumour markers (Acid Ph., PAP, PSA) showed a significant reduction in all patients defined as responders both in the epirubicin and doxorubicin arm (Figure 1 ). The aforementioned markers showed a progressive increase in patients defined as non responders (Figure 2 ). After 12 courses of chemotherapy, five patients in partial remission (four epirubicin and one doxorubicin) showed recalcification of at least one osteolytic lesion with no change in the osteoblastic bone metastases. Seven patients with partial remission (five epirubicin and two doxorubicin) showed a 50% regression in the cross-sectional area of the predominant metastatic site (lung) and stabilisation of bone metastases with at least 50% reduction in levels of bone (WBR%, BGP, Alk Ph, UHOP/Cr) and prostatic tumour markers (Acid.Ph., PAP, PSA). Twelve cases with exclusively osteoblastic metastases (eight epuribicin and four doxorubicin) showed a reduction <50% in uptake areas on the bone scan and a reduction of more than 50% in the levels of bone and prostatic tumour markers with disappearance of pain and significant improvement in performance status.
Using the NPCP criteria alone, there were 9/45 (20%) responders in the epirubicin arm and 3/21 (14.8%) in the doxorubicin arm. This difference was not statistically significant (P = 0.46). The histological analysis of the transiliac bone biopsy specimens showed a significant reduction both of neoplastic invasion and new bone formation in six out of 12 patients after 12 courses of epirubicin and in two out of five patients after 12 courses of doxorubicin (Figure 3, al vs a2) .
The median duration of partial remission in epirubicin and doxorubicin-treated patients was similar (10.8 months vs 8.8; P= 0.35).
At the end of 24 months of follow-up (range 12-65), the Chemotherapy courses Figure 2 Mean responses ± standard errors for 24 h whole body retention (WBR%), bone Gla-protein (BGP), serum alkaline phosphatase (Alk.Ph.), urinary hydroxyproline/creatinine ratio (UHOP/Cr), pain intensity (VAS), serum acid phosphatase (Acid Ph.), prostatic acid phosphatase (PAP) and prostatic specific antigen (PSA) in patients defined non responders during 12 courses of epirubicin (A) or doxorubicin (x). 'P value' shows the significant difference between values pretreatment with post treatment. (*P < 0.05; **P < 0.01; ***P < 0.001).
survival rate in 48 patients receiving epirubicin was 73% after 6 months, 54% after 12 months, and 29% after 18 months, with an overall median survival of 12.5 months (range 1.5-24+). The survival rate in 24 patients receiving doxorubicin was 58% after 6 months, 29% after 12 months, and 4% after 18 months, with an overall median survival of 8.0 months (range 1.5-21). The difference between the two survival curves was significant (P= 0.042) (Figure 4 ). Toxicity Toxicity is summarised in Table V. The predominant adverse effects of chemotherapy were mainly cardiotoxicity and myelotoxicity. The PEP/LVET ratio increased significantly in five out of 45 patients (11.1%) in the epirubicin arm and in ten out of 21 (47.6%) in the doxorubicin arm during the first 12 courses of chemotherapy (P = 0.014). The PEP/LVET ratio increased significantly in two patients in the epirubicin arm and in four in the doxorubicin arm during three further courses. Clinical congestive heart failure was not observed in patients receiving epirubicin, while it occurred in four patients receiving doxorubicin between the 9th and 13th course.
Grade 2-3 leukopenia occurred in eight out of 45 patients receiving epirubicin (17.7%) and in 11 out of 21 receiving doxorubicin (52.3%) after 12 courses of chemotherapy (P= 0.03).
Grade 2-3 anaemia was observed in seven out of 45 patients receiving epirubicin (15.5%) and in 12 out of 21 receiving doxorubicin (57.1%) after 12 courses of chemotherapy (P = 0.01).
Nausea was rarely observed in both treatment groups and was less severe in the epirubicin arm (in which no grade 3, four grade 2 and six grade 1 were recorded vs two grade 3, six grade 2 and nine grade 1 in the doxorubicin arm). Grade 2-3 hair loss occurred in five epirubicin treated patients and 11 doxorubicin treated patients after 12 courses of chemotherapy. Complete alopecia was observed in only two patients in the doxorubicin arm.
Chemotherpay was delayed during the first 12 courses in 16 patients (five epirubicin and 11 doxorubicin) because of cardiotoxicity and myelosuppression. After 12 courses, 24 patients (14 epirubicin and ten doxorubicin) required repeated delays because of toxicities. Treatment was discontinued after 12 courses in seven patients (two epirubicin and five doxorubicin) because of cardiotoxicity and/or persistent myelosuppression.
Discussion
Systemic chemotherapy studies in advanced prostatic cancer have been few and have obtained mixed results (Torti et al., 1983; Eisenberger & Abrams, 1988; Francini et al., 1989) . This is partly due to the excessive length of previous hormonal therapy or radiotherapy and partly to the poor responsiveness of prostatic neoplastic cells to the most common antiproliferative agents. In addition, many patients are elderly, anaemic, and in pain from bone metastases which causes decreased mobility, thus, making monitoring in outpatients difficult. Considering that all the patients in this study were in an advanced stage of the disease (stage D2), the effectiveness of our weekly schedule of chemotherapy appears to be satisfactory. However, it must be noted that chemotherapy was immediately started when bone and prostatic tumour markers showed a significant increase and before a decrease in performance status occurred.
It is notable that chemotherapy (epirubicin or doxorubicin) achieved a rapid palliative response with improvement in bone pain. The quality of life, which is the major endpoint for evaluating the effectiveness of a treatment, improved in most of the patients, and many of them were free to carry out their daily activities. Moreover, bone markers (WBR%, BGP, Alk Ph, UHOP/Cr) and prostatic tumour markers (Acid Ph., PAP, PSA) dropped significantly in responsive patients.
Considering the great difficulties involved in the assessment of response criteria in advanced prostatic cancer, the use of bone and prostatic tumour markers, together with other evaluation criteria such as performance status, bone pain and a, (Hetherington et al., 1988; Speights, 1989; Jacobs et al., 1980 Jacobs et al., ): al., 1991 Francini et al., 1992) .
(i) the cell population consists of several cell types, some dered as responders, using either of which are hormone-dependent and some hormoneaddition with our criteria, have independent; lution during and after chemo-(ii) the hormone-independent tumour population can be present at the onset of the disease, or more frequently, narkers which were evaluated all appear during its development; esponse to treatment. However, (iii) it is known that prostatic cancer cells appear to directly ,ignificance and is probably the stimulate osteoblast activity, and a prostatic osteoblastic factor has been described that stimulates both DNA results obtained with the weekly synthesis, and osteoblastic and fibroblastic proliferaful to focus on some characteristion. Thus, the significant reduction in bone pain and in the levels of bone and prostatic tumour markers during chemotherapy is probably due to a reduction in number and/or activity of the tumour cell populations (Francini et al., 1988; Scher et al., 1990; Hussain et al., 1991; Francini et al., 1992) . This is also supported by the histopathology of bone biopsy, which demonstrated a significant reduction in invading neoplastic cells and in new bone formation in responders.
Regarding cardiac toxicity, only five patients receiving epirubicin showed a significant increase in the PEP/LVET m ma ratio without cardiac failure during 12 courses; in one of these cases, the PEP/LVET ratio reverted spontaneously to baseline 20 days after withdrawal of treatment. In another b _ four patients, a considerable improvement was observed after pharmacological treatment with non-digitalis inotropic agents 12 18 24 (Neri et al., 1988) . Conversely, ten patients receiving doxoMonths rubicin showed an increase of PEP/LVET during the first 12 courses, and of these four had clinical congestive heart a, 48 patients treated with epirufailure. loxorubicin.
Leukopenia and serious anaemia were observed in fewer cases in the epirubicin arm compared with the doxorubicin arm. In these cases, cytotoxic treatment had to be delayed for a week or more, and the patients needed repeated blood transfusions. However, these side effects were not always linked to drug myelotoxicity; in fact, decreases in haemoglobin levels, which are an extremely important prognostic parameter, often reflected the metastatic invasion of bone marrow or uraemic marrow suppression and sometimes urinary blood losses (Berry et al., 1979; Newling, 1985) . Nevertheless, chemotherapy alone produced an improvement of the bone marrow reserve in at least 11 patients.
As to the comparative efficacy of the two anthracyclines, our findings suggest a similar response rate of epirubicin vs doxorubicin after 12 courses (37.7% vs 33.3%) and a significantly longer survival (median: 12.5 vs 8.0 months). The difference in cardiotoxicity and myelotoxicity between the two treatment arms and consequently the longer duration of treatment probably accounts for the better survival seen in patients receiving epirubicin. However, this significant difference may represent a false-positive observation due to the limited number of patients studied.
In conclusion, our data indicate that in patients with advanced prostatic cancer who have relapsed after hormonal therapy a weekly epirubicin regimen may give rapid palliative results, similar to that of doxorubicin, but with fewer side effects.
